Clinical trials: Endocrine System Disorder
Type 2 Diabetes
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it…
- Trial name
- NCT04373967
- Testing
- Victoza®., Metformin Hydrochloride, TQZ2451
- Where
- 46 sites in China
- Volunteers
- 424 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide (NNC0113-0217) in subjects with mild…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02016911
- Testing
- semaglutide
- Where
- 6 sites in Czechia, Poland and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcer
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™).
- Trial name
- NCT03312595
- Testing
- Restrata TM Wound Matrix
- Where
- 5 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acera Surgical, Inc.
Ovarian Neoplasms
Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients
This is a multi-center, observational study in Japan. Patients with newly diagnosed FIGO stage III - IV advanced OC will be enrolled sequentially.
- Trial name
- CHRISTELLE (NCT04222465)
- Where
- 20 sites in Japan
- Volunteers
- 207 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT03966911
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Where
- 15 sites in United States
- Volunteers
- 335 people
- Sponsor
- Medtronic MiniMed, Inc.
Hypogonadism
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
- Trial name
- NCT06385509
- Testing
- Jatenzo Oral Product
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Tolmar Inc.
Healthy, Type 2 Diabetes Mellitus
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04586907
- Testing
- LY3537021
- Where
- Singapore
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Brain Injuries, Growth Hormone Deficiency
Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury
To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.
- Trial name
- NCT00555009
- Testing
- Genotropin
- Where
- 9 sites in France, Italy and 4 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
Thyroid Neoplasms
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any…
- Trial name
- RIFTOS MKI (NCT02303444)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors
- Where
- 34 sites in United States, Algeria and 17 more
- Volunteers
- 667 people
- Sponsor
- Bayer
Diabetic Nephropathy
An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
This study aims to evaluate the safety and efficacy of MT-3995 administered over the longer term, following MT-3995-J05 study.
- Trial name
- NCT02676401
- Testing
- MT-3995 Low, MT-3995 Middle, MT-3995 High
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy of a nutritional formula in patients with type 2 diabetes.
- Trial name
- NCT01188200
- Testing
- Experimental nutritional formula #M979, Standard food
- Where
- 11 sites in Russia
- Volunteers
- 168 people
- Sponsor
- Abbott Nutrition
Type-II Diabetes
Postbiotic MBS and Metformin Combination in Patients With T2DM
The primary objective is to evaluate the effect of MBS treatment in human subjects, and to validate its impact on intestinal flora and diabetes symptoms on diabetic patients undertaking metformin.
- Trial name
- NCT04639492
- Testing
- MBS oral solution
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- Microbio Co Ltd
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07811271
- Testing
- BG-C9074, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- BeOne Medicines
Diabetes Mellitus, Type 2
Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments
Earlier protocol ID was NN1250-4630, protocol ID is changed to NN1535-7774. The purpose of this study is to collect blood glucose values and activity data in patients with type 2 diabetes for approximately 12 weeks using…
- Trial name
- NCT04809311
- Testing
- Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1)
- Where
- Denmark
- Volunteers
- 156 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Project VerioVue Enhancements - Neonate Study
The goal of this performance evaluation is to compare the blood glucose results obtained using the VerioVue Blood Glucose Monitoring system (BGMS) with those obtained from a validated comparator method (iSTAT 1 Analyser) using…
- Trial name
- NCT06052371
- Testing
- VerioVue (Enhancements) blood glucose monitoring system
- Where
- 3 sites in United Kingdom
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- LifeScan Scotland Ltd
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Diabetes Mellitus Type 2
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.
- Trial name
- NCT01889667
- Testing
- ORMD-0801 Dose # 1, ORMD-0801 Dose # 2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oramed, Ltd.
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.